Webcast: How Does the Public View CER & Cost-Cutting Measures?
|Date:||December 22nd, 2011|
|Time:||11:00AM - 12:30PM|
|Contact Name:||Debbie Zeldow|
|Related Topics:||Drug Development, Federal Funding, Medical Innovation, Policy|
Webcast Briefing: Moving Along the Guide Rails - How Does the Public View Comparative Effectiveness Research & Cost-Cutting Measures?
A Discussion of Survey Results across Four Countries on the Use and Practice of CER.
Evidence from comparative effectiveness research (CER) is increasingly being used in health care treatment decision-making around the globe. A desire to reduce health care costs can drive the use of head-to-head clinical trials, such as in recent, unprecedented trials comparing the safety and effectiveness of treatments for wet age-related macular degeneration (wAMD). The results of a trial like this can become a major factor in coverage and treatment decisions.
In a time where health care spending is sky-rocketing, where will the public draw the line?
Join the Alliance for Aging Research and the Harvard School of Public Health as we discuss the results of a 4-country public opinion survey (U.S., U.K., Italy and Germany) that explores public views on comparative effective research, its promise and its limitations. The survey results are a telling reflection across cultures and countries of how the public views the use of research and cost as a means of making decisions on health care access and coverage.
- Dan Perry, President & CEO, Alliance for Aging Research
- Robert J. Blendon, Sc.D., Harvard School of Public Health
- Joe V. Selby MD MPH, Executive Director, PCORI